Integra LifeSciences (NASDAQ:IART) Releases FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $2.41 to $2.51 for the period, compared to the consensus estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Trading Down 1.5 %

IART traded down $0.35 during trading on Thursday, hitting $23.25. The company’s stock had a trading volume of 309,933 shares, compared to its average volume of 603,022. The stock’s fifty day moving average price is $23.74 and its 200-day moving average price is $21.84. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $41.17. The firm has a market capitalization of $1.79 billion, a P/E ratio of -258.58, a PEG ratio of 0.73 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the previous year, the business earned $0.89 earnings per share. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. Analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IART shares. Citigroup upped their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $23.00.

Insider Activity at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.10% of the stock is currently owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.